Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › adalimumab

adalimumab

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of adalimumab

132 trials tracked of adalimumab: 102 in phase 3 or 4 and 49 with published results. The most-cited published study has 917 citations.

132Trials tracked
102Phase 3 & 4
0Recruiting
49With published results
Phase distribution
Phase 4 23 Phase 3 79 Phase 2 19 Phase 1 1 Other / NA 10
  1. Phase 3 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease Completed · 917 cited
  2. Phase 3 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis Completed · 730 cited
  3. Phase 3 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed · 664 cited
  4. Phase 3 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed · 514 cited
  5. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 299 cited
  6. Phase 3 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis Completed · 282 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis Completed · 186 cited
  2. Phase 3 A Study in Moderate to Severe Rheumatoid Arthritis Completed · 164 cited
  3. Phase 4 Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically Completed · 156 cited
  4. Phase 3 A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate Completed · 150 cited
  5. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 148 cited
  6. Phase 3 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed · 111 cited
  7. Phase 3 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis Completed · 99 cited
  8. Phase 4 Triple Combination Therapy in High Risk Crohn's Disease (CD) Completed · 91 cited
  9. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 90 cited
  10. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 90 cited
  11. Phase 3 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) Completed · 85 cited
  12. Phase 3 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease Completed · 85 cited
  13. Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Completed · 82 cited
  14. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed · 82 cited
  15. Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis Completed · 80 cited
  16. Phase 4 Treatments Against RA and Effect on FDG-PET/CT Completed · 74 cited
  17. Phase 3 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 Completed · 62 cited
  18. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 60 cited
  19. Phase 3 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed · 58 cited
  20. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 55 cited
  21. Phase 3 A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). Completed · 54 cited
  22. Phase 4 Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis Completed · 53 cited
  23. Phase 3 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease Completed · 53 cited
  24. Phase 4 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Completed · 44 cited
  25. Phase 3 A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed · 44 cited
  26. Phase 3 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting Completed · 44 cited
  27. Phase 4 A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects Completed · 40 cited
  28. Phase 3 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis Completed · 33 cited
  29. Phase 3 Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA Completed · 33 cited
  30. Phase 3 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) Completed · 30 cited
  31. Phase 3 Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) Completed · 25 cited
  32. Phase 4 Adalimumab in JIA-associated Uveitis Stopping Trial Completed · 24 cited
  33. Phase 3 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis Completed · 20 cited
  34. Phase 4 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Completed · 15 cited
  35. Phase 3 A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis Completed · 14 cited
  36. Phase 3 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Completed · 13 cited
  37. Phase 4 Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan Completed · 12 cited
  38. Phase 3 Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Completed · 10 cited
  39. Phase 3 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Completed · 8 cited
  40. Phase 3 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Completed · 7 cited
  41. Phase 4 Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial Completed · 3 cited
  42. Phase 3 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed · 2 cited
  43. Phase 3 A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis Completed
  44. Phase 4 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis Completed

Showing the 50 most-cited and recently-updated of 132 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TNF inhibitors may be effective for juvenile idiopathic arthritis in patients with DiGeorge syndrome
Diabetes & Endocrinology Sys. Review
TNF inhibitors may be effective for juvenile idiopathic arthritis in patients with DiGeorge syndrome Biologic treatments show promise for children with DiGeorge syndrome
This case report and literature review examines the management of juvenile idiopathic arthritis (JIA) in children with DiGeorge syndrome (DG…
Children with both DiGeorge syndrome and juvenile idiopathic arthritis may find relief from joint pain using specific biologic medications.
Frontiers Jul 30, 2026
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
Rheumatology Sys. Review
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Jul 18, 2026
Adalimumab and its biosimilar IBI303 show distinct response clusters in ankylosing spondylitis
Allergy & Immunology RCT
Adalimumab and its biosimilar IBI303 show distinct response clusters in ankylosing spondylitis Trial shows two different ways patients respond to adalimumab
This Phase III randomized controlled trial of 438 patients with active ankylosing spondylitis identified two longitudinal response clusters.…
A new study identifies two distinct groups of people with ankylosing spondylitis who react differently to the same treatment.
Frontiers Jul 5, 2026
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab
Rheumatology RCT
Upadacitinib 15 mg daily achieves DAS28-CRP ≤3.2 in 43.3% of patients versus 22.4% for adalimumab Trial shows upadacitinib outperforms adalimumab for rheumatoid arthritis patients
This randomized controlled trial of 492 patients with rheumatoid arthritis and prior TNFi failure found upadacitinib 15 mg daily superior to…
A new trial finds that upadacitinib works better than adalimumab for people with rheumatoid arthritis who did not respond well to previous t…
Jul 4, 2026
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Dermatology RCT
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
Jun 1, 2026
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications
Rheumatology FDA Approval
FDA Approves Hadlima (adalimumab) for Multiple Inflammatory Indications FDA approves Hadlima, a new biosimilar for several inflammatory diseases.
The FDA approved Hadlima (adalimumab) for several inflammatory conditions including rheumatoid arthritis, juvenile idiopathic arthritis, pso…
The FDA approved Hadlima (adalimumab) for treating conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. It is a biosimilar,…
FDA May 5, 2026
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
Dermatology RCT
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis New drug ixekizumab shows promise for children with arthritis
This multicentre, open-label, phase 3 study evaluated ixekizumab in 101 children with enthesitis-related arthritis or juvenile psoriatic art…
A phase 3 study found ixekizumab helped many children with arthritis meet response criteria at week 16, with mostly mild side effects report…
May 1, 2026
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Pediatrics Meta-analysis
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
May 1, 2026
Sudden sensorineural hearing loss risk factors in ankylosing spondylitis patients on adalimumab plus methotrexate
Neurology Cohort
Sudden sensorineural hearing loss risk factors in ankylosing spondylitis patients on adalimumab plus methotrexate Could long-term arthritis treatment raise your risk of sudden hearing loss?
This retrospective case-control analysis drew on 2,564 ankylosing spondylitis patients at Henan Provincial People's Hospital (2015-2024), co…
Patients with long-term ankylosing spondylitis taking adalimumab and methotrexate are more likely to experience sudden hearing loss than tho…
Frontiers Apr 16, 2026
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Gastroenterology Phase IV
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
CT.gov Mar 27, 2026